11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Vaginal misoprostol for cervical ripening and induction of labour

      systematic-review
      , ,
      Cochrane Pregnancy and Childbirth Group
      The Cochrane Database of Systematic Reviews
      John Wiley & Sons, Ltd

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Misoprostol (Cytotec, Searle) is a prostaglandin E1 analogue widely used for off‐label indications such as induction of abortion and of labour. This is one of a series of reviews of methods of cervical ripening and labour induction using standardised methodology.

          Objectives

          To determine the effects of vaginal misoprostol for third trimester cervical ripening or induction of labour.

          Search methods

          The Cochrane Pregnancy and Childbirth Group's Trials Register (November 2008) and bibliographies of relevant papers. We updated this search on 15 February 2012 and added the results to the awaiting classification section.

          Selection criteria

          Clinical trials comparing vaginal misoprostol used for third trimester cervical ripening or labour induction with placebo/no treatment or other methods listed above it on a predefined list of labour induction methods.

          Data collection and analysis

          We developed a strategy to deal with the large volume and complexity of trial data relating to labour induction. This involved a two‐stage method of data extraction.

          We used fixed‐effect Mantel‐Haenszel meta‐analysis for combining dichotomous data.

          If we identified substantial heterogeneity (I² greater than 50%), we used a random‐effects method.

          Main results

          We included 121 trials. The risk of bias must be kept in mind as only 13 trials were double blind.

          Compared to placebo, misoprostol was associated with reduced failure to achieve vaginal delivery within 24 hours (average relative risk (RR) 0.51, 95% confidence interval (CI) 0.37 to 0.71). Uterine hyperstimulation, without fetal heart rate (FHR) changes, was increased (RR 3.52 95% CI 1.78 to 6.99).

          Compared with vaginal prostaglandin E2, intracervical prostaglandin E2 and oxytocin, vaginal misoprostol was associated with less epidural analgesia use, fewer failures to achieve vaginal delivery within 24 hours and more uterine hyperstimulation. Compared with vaginal or intracervical prostaglandin E2, oxytocin augmentation was less common with misoprostol and meconium‐stained liquor more common.

          Lower doses of misoprostol compared to higher doses were associated with more need for oxytocin augmentation and less uterine hyperstimulation, with and without FHR changes.

          We found no information on women's views.

          Authors' conclusions

          Vaginal misoprostol in doses above 25 mcg four‐hourly was more effective than conventional methods of labour induction, but with more uterine hyperstimulation. Lower doses (25 mcg four‐hourly or less) were similar to conventional methods in effectiveness and risks. The authors request information on cases of uterine rupture known to readers. The vaginal route should not be researched further as another Cochrane review has shown that the oral route of administration is preferable to the vaginal route. Professional and governmental bodies should agree guidelines for the use of misoprostol, based on the best available evidence and local circumstances.

          [Note: The 27 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.]

          Plain language summary

          Vaginal misoprostol is effective in inducing labour but more research is needed on safety

          Sometimes it is necessary to bring on labour artificially because of safety concerns for the mother or baby. Misoprostol is a hormone given by insertion through the vagina or rectum, or by mouth to ripen the cervix and bring on labour. The review of 121 trials found that larger doses of misoprostol are more effective than prostaglandin and that oxytocin is used in addition less often. However, misoprostol also increases hyperstimulation of the uterus. With smaller doses, the results are similar to other methods. The trials reviewed are too small to determine whether the risk of rupture of the uterus is increased. More research is needed into the safety and best dosages of misoprostol. Another Cochrane review has shown that the oral route of administration is preferable to the vaginal route.

          Related collections

          Most cited references337

          • Record: found
          • Abstract: found
          • Book: not found

          Cochrane Handbook for Systematic Reviews of Interventions

          Healthcare providers, consumers, researchers and policy makers are inundated with unmanageable amounts of information, including evidence from healthcare research. It has become impossible for all to have the time and resources to find, appraise and interpret this evidence and incorporate it into healthcare decisions. Cochrane Reviews respond to this challenge by identifying, appraising and synthesizing research-based evidence and presenting it in a standardized format, published in The Cochrane Library (www.thecochranelibrary.com).<p><i>The Cochrane Handbook for Systematic Reviews of Interventions</i> contains methodological guidance for the preparation and maintenance of Cochrane intervention reviews. Written in a clear and accessible format, it is the essential manual for all those preparing, maintaining and reading Cochrane reviews. Many of the principles and methods described here are appropriate for systematic reviews applied to other types of research and to systematic reviews of interventions undertaken by others. It is hoped therefore that this book will be invaluable to all those who want to understand the role of systematic reviews, critically appraise published reviews or perform reviews themselves.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            PELVIC SCORING FOR ELECTIVE INDUCTION.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Absorption kinetics of misoprostol with oral or vaginal administration.

              To compare the pharmacokinetics of vaginal and oral administration of the prostaglandin E1 analogue, misoprostol. Twenty women received 400-micrograms doses of misoprostol either orally or as tablets placed in the vagina. Serum levels of principal metabolite, misoprostol acid, were measured at 7.5, 15, 30, 45, 60, 90, 120, and 240 minutes. The first ten women were pregnant and undergoing first-trimester abortions, and the last ten were not pregnant and had additional blood sampling at 360 minutes. We compared the pharmacokinetics of misoprostol acid after oral and vaginal administration. All 20 subjects completed the study. The maximum mean (+/- standard deviation [SD]) of misoprostol acid differed significantly between the oral and vaginal groups (277 +/- 124 compared with 165 +/d- 86 pg/mL, respectively; P = .03, analysis of variance), as did the mean +/- SD time to peak levels (34 +/- 17 compared with 80 +/- 27 minutes, respectively; P < .001) and areas under the misoprostol concentration versus time curve (mean +/- SD) up to 4 hours (n = 20,273.3 +/- 110.0 compared with 503.3 +/- 296.7 pg.hour/mL, respectively; P = .033) and up to 6 hours (n = 10, 300.0 +/- 103.3 compared with 956.7 +/- 541.7 pg.hour/mL, respectively; P = .029). The extent of absorption was highly variable among subjects in each group. There are significant differences in the pharmacokinetics of misoprostol administered by vaginal and oral routes that may explain the difference observed in clinical efficacy. Assuming that the pharmacologic effect of misoprostol is related to its concentration in the plasma, our observation of the prolonged serum concentrations in the vaginal group suggests that vaginal administration could be dosed at longer intervals than oral.
                Bookmark

                Author and article information

                Contributors
                justhof@gmail.com
                Journal
                Cochrane Database Syst Rev
                Cochrane Database Syst Rev
                14651858
                10.1002/14651858
                The Cochrane Database of Systematic Reviews
                John Wiley & Sons, Ltd (Chichester, UK )
                1469-493X
                6 October 2010
                October 2010
                20 November 2012
                : 2010
                : 10
                : CD000941
                Affiliations
                University of the Witwatersrand, University of Fort Hare, Eastern Cape Department of Health deptDepartment of Obstetrics and Gynaecology, East London Hospital Complex Frere and Cecilia Makiwane Hospitals Private Bag X 9047 East London Eastern Cape South Africa 5200
                World Health Organization deptUNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research 20 Avenue Appia Geneva Switzerland 1211
                5 Chemin de La Voie‐Creuse Geneva Switzerland 1202
                Article
                PMC7061246 PMC7061246 7061246 CD000941.pub2 CD000941
                10.1002/14651858.CD000941.pub2
                7061246
                20927722
                30cd9bd4-95f4-4aab-8c9f-032441ee17d6
                Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
                History
                Categories
                Pregnancy & childbirth
                Induction of labour

                Comments

                Comment on this article